The DOCK5 Knockout Jurkat Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-lymphocyte line, carrying targeted disruption of the DOCK5 gene. This polyclonal pool serves as a loss-of-function model for dissecting DOCK5-dependent signaling pathways without requiring single-cell cloning, offering a genetically heterogeneous yet functionally relevant population for interrogating actin cytoskeletal dynamics and migratory behavior. The polyclonal nature preserves population-level diversity while disrupting gene function across the pool, enabling robust assessment of DOCK5??s role in T-cell biology and oncogenic processes.
The parental Jurkat cell line is an immortalized human T-lymphocyte model established from the peripheral blood of a 14-year-old male with T-cell acute lymphoblastic leukemia (T-ALL). These cells are widely employed in immunology and cancer biology to study T-cell receptor (TCR) signaling, activation mechanisms, and leukemic transformation. Their malignant derivation and retention of T-cell characteristics make them particularly suitable for exploring molecular determinants of T-cell migration, immune synapse formation, and leukemia invasion, providing a clinically relevant backdrop for DOCK5 functional analysis.
DOCK5 encodes a guanine nucleotide exchange factor (GEF) that operates as a bipartite activator of the small GTPases Rac1 and Cdc42, partnering obligatorily with ELMO1 or ELMO2 adaptor proteins. This ELMO-DOCK5 complex is recruited to the plasma membrane following integrin-mediated adhesion or stimulation by growth factor receptors such as EGFR and PDGFR, and is regulated upstream by RhoG and chemokine receptors. Upon activation, DOCK5 catalyzes GDP/GTP exchange on Rac1 and Cdc42, initiating downstream signaling through effectors including PAK1, the WAVE regulatory complex, and the Arp2/3 complex, leading to cofilin phosphorylation and actin polymerization. These events drive lamellipodia formation, focal adhesion turnover, and directed cell migration. Additionally, DOCK5 interacts with the CRK adaptor protein, linking it to broader cytoskeletal remodeling networks.
Within the Jurkat T-cell environment, DOCK5-mediated actin reorganization is critical for T-cell trafficking, immunological synapse assembly, and potentially leukemic cell dissemination. Abrogation of DOCK5 function disrupts Rac1/Cdc42 signaling cascades that underpin chemokine-driven migration and integrin-dependent adhesion, processes essential for normal immune surveillance and pathological metastasis. Consequently, this polyclonal knockout model provides a physiologically relevant platform to investigate how DOCK5 loss remodels cytoskeletal dynamics in a T-ALL background, offering insights into tumor invasion mechanisms and immune cell motility defects.
Key research applications include performing Transwell migration assays and adhesion assays to quantify DOCK5-dependent motility, Rac1/Cdc42 activation pull-downs (G-LISA) to assess GTPase signaling, immunofluorescence staining for F-actin and focal adhesion proteins to visualize cytoskeletal architecture, western blotting for PAK1/cofilin phosphorylation to monitor downstream effector activity, and flow cytometry to evaluate integrin surface expression. These assays support drug target validation, mechanistic studies of T-cell signaling, and exploration of metastasis biology. For further information or to discuss specific experimental requirements, please contact Ascent Research.
